PYC Therapeutics LimitedASX: PYC

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by PYC Therapeutics Limited via ASX

Filed with ASX ·

pyctx.com | ACN 098 391 961 1 29 July 2026 Q2 2026 SHAREHOLDER UPDATE • PYC is a biotechnology company developing a pipeline of precision medicines designed to change the lives of patients who have genetic diseases and no treatment options available today • The Company...

View Attachment

6ix hasn’t read this filing yet.

PYC Therapeutics Limited on 6ix

Earlier from PYC Therapeutics

Later from PYC Therapeutics

All PYC Therapeutics news releases